Evotec AG has entered a strategic partnership with the Harvard Stem Cell Institute (HSCI) to identify compounds that prevent or slow down motor neuron loss in amyotrophic lateral sclerosis (ALS). The collaboration will leverage motor neuron assays based on ALS patient-derived induced pluripotent stem (iPS) cells developed by Dr. Lee Rubin and Dr. Kevin Eggan, scientists and professors at HSCI, with Evotec’s drug discovery infrastructure and expertise, to identify compounds against ALS. Fin...